{"favorite_id": 10154, "calc_type": "diagnostic_criteria", "dosing": false, "full_title_en": "International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis", "short_title_en": "IWG 2 Criteria for Alzheimer's ", "medium_description_en": "<span id=\"docs-internal-guid-19dc0de2-7fff-dbdb-ee73-f372c63b7840\">Diagnoses Alzheimer's disease (AD), newer than <calculator id=\"10151\">NINCDS-ADRDA Criteria</calculator>.", "short_description_en": "Alzheimer's diagnosis.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Dementia", "Alzheimer's Disease"], "specialty_en": ["Psychiatry", "Geriatrics", "Neurology", "Hospitalist Medicine", "Internal Medicine", "Palliative Care/Hospice"], "chief_complaint_en": ["Neurologic Deficit"], "system_en": ["Neurologic", "Psychiatric"], "search_abbreviation_en": ["Alzheimer's disease", "alzheimers disease", "Alzheimer's", "alzheimers", "alzhimers", "iwg2", "iwg 2", "criteria", "ad", "cognitive disorder", "memory function"], "slug": "international-working-group-iwg-2-criteria-alzheimers-disease-diagnosis", "seo": {"meta_description_en": "The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis diagnoses Alzheimer\u2019s disease (AD).", "keywords_en": "Alzheimer's disease, alzheimers disease, Alzheimer's, alzheimers, alzhimers, iwg2, iwg 2, criteria, nincds-adrda, dementia, cdr scale, clinical dementia rating, cdr, ad"}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the&nbsp;IWG 2 Criteria for Alzheimer's Disease and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the&nbsp;IWG 2 Criteria for Alzheimer's Disease and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Positive diagnosis for typical AD = selection of all criteria in&nbsp;Part A + &ge;1 item in&nbsp;Part B. For other types of AD including atypical, mixed, and preclinical AD, see <a href=\"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70090-0/fulltext\" target=\"_blank\">Dubois 2014</a>.</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Part A: Specific clinical phenotype (must have both)</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Early significant episodic memory impairment (isolated or associated with cognitive/behavioral changes suggesting mild cognitive impairment or dementia syndrome) that includes both of the following:</p>\n<ol>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gradual progressive change in memory function for &gt;6 months.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Objective evidence of hippocampal amnestic syndrome* based on significantly impaired performance on episodic memory test with established specificity for AD, e.g. cued recall, <a href=\"https://eprovide.mapi-trust.org/instruments/free-and-cued-selective-reminding-test-and-free-and-cued-selective-reminding-test-immediate-recall\" target=\"_blank\">Free and Cued Selective Reminding Test</a>.</p>\n</li>\n</ol>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Part B: In-vivo evidence (must have &ge;1)</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">CSF: decreased A&beta;<sub>1-42</sub>&nbsp;<em>and</em> increased P-tau or T-tau</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Amyloid PET: increased tracer retention</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Genetic testing: AD autosomal dominant mutation in PSEN1, PSEN2, or APP genes</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">*Hippocampal amnestic syndrome may be difficult to identify in later stages, in which case in-vivo evidence of Alzheimer&rsquo;s pathology in the presence of dementia syndrome may be sufficient.</p>\n<p>&nbsp;</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"182\" /><col width=\"266\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Exclusion criteria** for typical AD (if any are present, diagnosis is not typical AD)</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">History</p>\n</td>\n<td>\n<p dir=\"ltr\">Sudden onset</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Early occurrence of gait disturbances, seizures, major and prevalent behavioral changes</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"4\">\n<p dir=\"ltr\">Clinical features</p>\n</td>\n<td>\n<p dir=\"ltr\">Focal neurological features</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Early extrapyramidal signs</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Early hallucinations</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cognitive fluctuations</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"5\">\n<p dir=\"ltr\">Other medical conditions severe enough to account for memory and related symptoms</p>\n</td>\n<td>\n<p dir=\"ltr\">Non-AD dementia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Major depression</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cerebrovascular disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Toxic, inflammatory, and metabolic disorders, all of which may require specific investigations</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">MRI FLAIR or T2 signal changes in the medial temporal lobe that are consistent with infectious or vascular insults</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">**Should also exclude concomitant pathologies (e.g. vascular lesions) and other causes of cognitive disorders or dementia.</p>\n<p><span style=\"font-size: 10pt; font-family: Arial; color: #0000ff; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&nbsp;</p>", "more_info_en": "", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70090-0/fulltext", "text": "Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29."}], "Other References": [{"href": "https://www.degruyter.com/view/j/dx.2016.3.issue-1/dx-2015-0031/dx-2015-0031.xml", "text": "Baker KG. Evaluation of DSM-5 and IWG-2 criteria for the diagnosis of Alzheimer's disease and dementia with Lewy bodies. Diagnosis (Berl). 2016;3(1):9-12."}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Bruno Dubois", "creator_info": {"about_en": "Bruno Dubois, MD, PhD, is a professor of neurology at University Pierre and Marie Curie in Paris, France. He is also the director of the Institute for Memory and Alzheimer\u2019s Disease at the Piti\u00e9-Salp\u00eatri\u00e8re Hospital in Paris, France. Dr. Dubois\u2019 primary research is focused on Alzheimer\u2019s disease, prodromal Alzheimer\u2019s disease, and Parkinson\u2019s disease dementia.", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-bruno-dubois.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Dubois+B%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "subheading", "subheading": "Part A: Specific clinical phenotype (must have both)", "subheading_instructions": "Early significant episodic memory impairment (isolated or associated with cognitive/behavioral changes suggesting mild cognitive impairment or dementia syndrome) that includes both of the following:"}, {"type": "toggle", "label_en": "Gradual progressive change in memory function for >6 months", "name": "parta1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Objective evidence of hippocampal amnestic syndrome", "name": "parta2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "Based on episodic memory test performance (e.g. cued recall); may be difficult to identify in later stages, in which case in-vivo evidence of Alzheimer\u2019s pathology in the presence of dementia syndrome may be sufficient", "optional": false}, {"type": "subheading", "subheading": "Part B: In-vivo evidence (must have \u22651)", "subheading_instructions": ""}, {"type": "toggle", "label_en": "<abbr title = \"Cerebrospinal fluid\">CSF</abbr>: decreased A\u03b2<sub>1-42</sub> <i>and</i> increased P-tau or T-tau", "name": "partb1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Amyloid <abbr title = \"Positron emission tomography\">PET</abbr>: increased tracer retention", "name": "partb2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Genetic testing: AD autosomal dominant mutation in PSEN1, PSEN2, or APP genes", "name": "partb3", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Exclusion criteria for typical AD: history", "subheading_instructions": "(if any are present, diagnosis is not typical AD)"}, {"type": "toggle", "label_en": "Sudden onset", "name": "history1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Early occurrence of gait disturbances, seizures, major and prevalent behavioral changes", "name": "history2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Exclusion criteria for typical AD: clinical features", "subheading_instructions": "(if any are present, diagnosis is not typical AD)"}, {"type": "toggle", "label_en": "Focal neurological features", "name": "clinical1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Early extrapyramidal signs ", "name": "clinical2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Early hallucinations", "name": "clinical3", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Cognitive fluctuations", "name": "clinical4", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Exclusion criteria for typical AD: other medical conditions", "subheading_instructions": "(if any are present, diagnosis is not typical AD)"}, {"type": "toggle", "label_en": "Non-AD dementia", "name": "other1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Major depression", "name": "other2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Cerebrovascular disease", "name": "other3", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Toxic, inflammatory, and metabolic disorders, all of which may require specific investigations", "name": "other4", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "MRI <abbr title = \"Fluid-attenuated inversion recovery\">FLAIR</abbr> or T2 signal changes in the medial temporal lobe that are consistent with infectious or vascular insults", "name": "other5", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(parta1 + parta2) == 2 && (partb1 + partb2 + partb3) > 0", "show_points": false, "default": 0, "optional": false}], "md5": "8241988a3da386aefeff4962e1070bc9", "related_calcs": [{"calcId": 10151, "short_title_en": "NINCDS-ADRDA Criteria for Alzheimer\u2019s", "slug": "nincds-adrda-criteria-alzheimers-disease"}, {"calcId": 10044, "short_title_en": "Montreal Cognitive Assessment (MoCA)", "slug": "montreal-cognitive-assessment-moca"}, {"calcId": 10233, "short_title_en": "Multiple Myeloma Diagnostic Criteria", "slug": "multiple-myeloma-diagnostic-criteria"}]}